Moxisylyte

Summary

Moxisylyte (CHEMBL159226) is an approved small molecule (ATC G04BE06); indicated across 2 conditions including cardiovascular disorder and erectile dysfunction.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BE06 (+1 more)
• Indications: 2 conditions
• Chemistry: 279.37 Da · C16H25NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL159226
Name	Moxisylyte
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4260
ATC	G04BE06, C04AX10
Molecular formula	C16H25NO3
Molecular weight	279.37
InChIKey	VRYMTAVOXVTQEF-UHFFFAOYSA-N

SMILES: CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C

IUPAC name: [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] acetate

Also known as: Carlytene, Erecnos, Moxisilita, Moxisylyte, Moxisylyte hcl, Moxisylyte hydrochloride, Moxivig, NSC-170448, Thymoxamine hcl, Thymoxamine hydrochloride, SID11111464, SID11111465

Parent form; salt/anhydrous children: CHEMBL1256739

Patent coverage: 442 distinct patent families (1,514 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Pyruvate kinase PKM, Alpha-2A adrenergic receptor, Neuronal acetylcholine receptor subunit alpha-4, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Adrenergic receptor alpha-2, Adrenergic receptor alpha, 5-hydroxytryptamine receptor 2C, Alpha-1A adrenergic receptor, Histamine H1 receptor, D(3) dopamine receptor, Kappa-type opioid receptor, Muscarinic acetylcholine receptor M1, Cytochrome P450 2D6, Cytochrome P450 1A2, Gamma-aminobutyric acid receptor subunit alpha-1, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 24 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PKM	7.9	Potency	12.6	nM	CHEMBL_ACT_4388161
PKM	7.9	Potency	12.6	nM	CHEMBL_ACT_4583824
ADRA2A	7.5	Kd	31.62	nM	CHEMBL_ACT_131615
HRH1	5.96	AC50	1100	nM	CHEMBL_ACT_25212598
ADRA2B	5.52	AC50	3000	nM	CHEMBL_ACT_25143786
CYP1A2	5.5	AC50	3162	nM	CHEMBL_ACT_6007932
ADRA1A	5.42	AC50	3800	nM	CHEMBL_ACT_25218128
P08482	5.1	Potency	7943	nM	CHEMBL_ACT_4799509
CYP1A2	5.1	AC50	7943	nM	CHEMBL_ACT_6024913
DRD3	5.03	AC50	9300	nM	CHEMBL_ACT_25193612
HTR2C	5	AC50	10000	nM	CHEMBL_ACT_25131891
CYP2D6	5	Potency	10000	nM	CHEMBL_ACT_4957656
CYP2D6	5	Potency	10000	nM	CHEMBL_ACT_5002510
CYP2D6	5	AC50	10000	nM	CHEMBL_ACT_6024034
CYP2D6	5	AC50	10000	nM	CHEMBL_ACT_6050271

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
erectile dysfunction	4	MONDO:0005362	EFO:0004234

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).